Akèy › Lekemi selil B › Texas
Etid klinik pou Lekemi selil B nan Texas
12 etid pou Lekemi selil B ap chèche patisipan nan sit nan Texas.
Vil nan Texas
Tèks ofisyèl etid la (Anglè)
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, Houston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06542250Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730), Dallas
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT04728893Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
- Texas Children's Hospital, Houston
- The Methodist Hospital, Houston
Ap rekriteFaz 1
Jiska laj 75 · Tout sèks · Mizajou Sep 16, 2026 · NCT06345027A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, Houston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06564038Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Houston
Ap rekriteFaz 3
Laj 18 a 18 · Tout sèks · Mizajou Sep 8, 2026 · NCT07509151Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)
- Texas Children's Hospital, Houston
Ap rekriteFaz 1
12 Months – 25 Years · Tout sèks · Mizajou Sep 4, 2026 · NCT05010564Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- University of Texas, Southwestern, Dallas
- Baylor Texas Children's Hospital, Houston
Ap rekriteFaz 2
Laj 7 a 25 · Tout sèks · Mizajou Aug 19, 2026 · NCT05082519A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Lumi Research, Kingwood
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05254743A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
- UT Southwestern Medical Center, Dallas
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT06708897The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- University of Texas(UT) Southwestern-Children's Medical Center, Dallas
Ap rekriteFaz 1/2
Laj 12 a 95 · Tout sèks · Mizajou Apr 15, 2026 · NCT04329728A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- MD Anderson, Houston
Ap rekriteFaz 2
Laj 18 a 66 · Tout sèks · Mizajou Mar 17, 2026 · NCT06859424Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
- Ut Southwestern, Dallas
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jan 22, 2026 · NCT06357754Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.